Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy

prnewswire.com
KRMD The article announces a new CEO, Matthew Hemstreet, who is expected to lead the company into its next phase of expansion and growth. The company is described as a leader in its field with a strong foundation and unique positioning to meet increasing demand for genomic integrity insights in cell and gene therapy.

KROMATID Names Matthew Hemstreet CEO as Company Advances Toward Market Leadership in Cell & Gene Therapy BOULDER, Colo., June 18, 2026 /PRNewswire/ -- KROMATID, a leader in structural genomic integrity analysis for the cell and gene therapy industry, today announced the appointment of Matthew Hemstreet as Chief Executive Officer, succeeding Interim CEO Terry Opgenorth.

Opgenorth was appointed Interim CEO during a pivotal period for the company and successfully guided KROMATID through a strategic transformation designed to strengthen its market position, sharpen its commercial focus, and establish a foundation for long-term growth. Under his leadership, KROMATID:

KROMATID announces Matt Hemstreet as new CEO

"Terry was instrumental in helping position KROMATID for its next stage of growth," said David Brunel, President of the Board of Directors. "His leadership strengthened our strategic direction, commercial execution, and organizational focus, leaving the company well-positioned for the future."

With KROMATID's strategic, technological, and commercial foundations firmly in place, the Board has appointed Matthew Hemstreet as Chief Executive Officer to lead the company's next phase of expansion.

Since joining KROMATID as Vice President of Global Marketing in 2024, Hemstreet has played a key role in the company's strategic and operational evolution. He brings more than a decade of leadership experience spanning global marketing, product management, and commercial strategy at Terumo Blood and Cell Technologies, Medtronic, Covidien, and others. Throughout his career, he has successfully launched more than 30 products and built high-performing teams focused on accelerating growth and delivering customer value.

"Matt combines deep cell therapy industry expertise with a proven ability to align strategy, execution, and innovation," said Opgenorth. "He understands both the scientific and commercial opportunities ahead of us, and I am confident he is the right leader to guide KROMATID through its next chapter."

As Chief Executive Officer, Hemstreet will focus on:

"I am honored to step into this role," said Hemstreet. "The demand for deeper genomic integrity insights has never been greater. KROMATID is uniquely positioned to help developers of advanced therapies better understand, characterize, and de-risk their products. Our focus moving forward is clear: scale our impact, expand our capabilities, and establish genomic integrity as a foundational quality metric across the industry."

The Board of Directors extends its gratitude to Terry Opgenorth for his leadership and contributions as Interim CEO; Opgenorth will continue to serve as a valued member of the board of directors and looks forward to supporting Hemstreet as he leads KROMATID into its next phase of growth and innovation.

About KROMATID

KROMATID is the leader in genomic structural analysis for cell and gene therapy developers, providing unparalleled clarity into chromosomal integrity. By combining proprietary imaging with advanced bioinformatics, KROMATID enables precise detection of structural variation and empowers developers to confidently advance therapies from discovery through regulatory approval. Learn more at www.kromatid.com

Media Contact

Amanda Ladas

Associate Director of Global Marketing

KROMATID

[email protected]

773-720-0709

SOURCE KROMATID